SAVE Moms and Babies Act of 2025
- Bill Number
- H.R. 685
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-01-23: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-24T08:10:22Z
AI-Generated Summary
Purpose of the Legislation
This bill, titled the "Support And Value Expectant Moms and Babies Act of 2025" (or "SAVE Moms and Babies Act of 2025"), aims to restrict access to abortion drugs by amending the Federal Food, Drug, and Cosmetic Act (FD&C Act). It prohibits the approval of new abortion drugs, bans investigational use exemptions for them, and adds stricter regulatory requirements for drugs already approved, with the goal of limiting their use while emphasizing support for pregnant women and unborn children.
Key Provisions
- Prohibitions on New Approvals and Investigations:
- The Food and Drug Administration (FDA) cannot approve any new applications to market abortion drugs.
- The FDA cannot grant investigational use exemptions (temporary permissions for testing drugs before full approval) for abortion drugs or for any research that knowingly destroys the unborn child of a pregnant woman.
- Existing investigational exemptions granted before the bill's enactment will be revoked after 3 years if they involve prohibited activities.
- Restrictions on Previously Approved Abortion Drugs (e.g., drugs like mifepristone already on the market as of the enactment date):
- No changes to drug labeling can expand use beyond 70 days of gestation (calculated from the first day of the last menstrual period) or allow dispensing without in-person administration by the prescribing healthcare practitioner.
- These drugs must be treated as prescription-only medications (under section 503(b)(1) of the FD&C Act, meaning they require a doctor's order and cannot be over-the-counter).
- A mandatory Risk Evaluation and Mitigation Strategy (REMS—a FDA program to manage known or potential serious risks of a drug) must include:
- Certification for prescribing healthcare practitioners (defined as licensed individuals authorized to prescribe certain drugs), excluding pharmacists; prescribers must demonstrate skills in assessing pregnancy duration, diagnosing ectopic pregnancies (when a fertilized egg implants outside the uterus), providing surgical interventions for complications like incomplete abortion or severe bleeding, ensuring access to facilities for blood transfusions or resuscitation, and reporting adverse events (harms like death, hospitalization, or infection) to the FDA and manufacturer using non-identifiable patient references and drug package serial numbers.
- Dispensing limited to in-person administration in clinics, medical offices, or hospitals by the certified prescriber—no pharmacy or other settings allowed.
- Requirement for prescribers to provide patients with documentation on serious complication risks and obtain patient acknowledgment.
- Mandatory reporting of all known adverse events (e.g., death, ectopic pregnancy, hospitalization, blood loss needing transfusion, infections like endometritis or sepsis) by manufacturers and prescribers to the FDA, without identifiable patient information.
- Reporting of drug administrations to comply with state laws or, if none exist, in the same way as surgical abortions.
- All other healthcare practitioners must report patient adverse events linked to abortion drugs to the FDA.
- Definitions:
- Abortion drug: Any drug or substance intended or used to intentionally end a known pregnancy by killing the unborn child, excluding cases aimed at live birth, removing a dead unborn child, or treating an ectopic pregnancy.
- Unborn child: A human organism from fertilization until birth (as defined in federal law).
- Adverse event: Includes death, ectopic pregnancy, hospitalization, transfusion-requiring blood loss, and various infections.
- Rule of Construction: States and the federal government can add further restrictions on abortion drugs under other laws, beyond this bill's requirements.
Significant Changes to Existing Law
- Bans New Pathways: Introduces outright prohibitions on FDA approvals and investigational exemptions for abortion drugs, which were previously possible under the FD&C Act's sections 505(b), 505(j), and 505(i). This halts development and testing of new options.
- Tightens Existing Approvals: Alters regulations for drugs like mifepristone by mandating in-person dispensing (reversing recent FDA allowances for mail-order), limiting gestational use to 70 days (aligning with but enforcing early limits), and imposing a comprehensive REMS with prescriber certification and reporting—stricter than current FDA oversight.
- Expands Reporting: Adds requirements for adverse event reporting by all involved parties, including non-prescribers, which goes beyond existing FDA pharmacovigilance (drug safety monitoring) rules.
- Ongoing Exemptions: Automatically rescinds pre-enactment investigational permissions after 3 years for prohibited uses, creating a phase-out not present in prior law.
Potential Impacts
- On Government Agencies: The FDA will face new limitations on its approval authority, increased administrative burdens for REMS enforcement, certification processes, and adverse event monitoring, potentially straining resources and requiring updated guidance or rulemaking.
- On Citizens: Pregnant women may have reduced access to abortion drugs, limited to early pregnancy and in-person settings, which could increase barriers (e.g., travel, costs) and shift reliance to surgical options or other care; it emphasizes support for expectant mothers but does not fund or detail such programs. Healthcare access could vary by state due to reporting ties.
- On International Relations: No direct impacts mentioned, though it could influence U.S. drug export/import policies or global pharmaceutical standards if abortion drugs are involved in international trade.
Main Stakeholders Affected
- Women and Pregnant Individuals: Primary users, facing restricted options for medication-based pregnancy termination.
- Healthcare Practitioners: Doctors and certified providers must meet new training and reporting standards; pharmacists are excluded from dispensing roles.
- Drug Manufacturers: Existing producers (e.g., of mifepristone) must comply with enhanced REMS and reporting; new entrants are barred.
- FDA and Regulators: Directly tasked with enforcement, approvals, and oversight.
- Unborn Children and Families: Bill language protects fetal life from drug-induced termination, potentially affecting anti-abortion advocacy groups.
- States: Can layer additional rules, impacting local healthcare systems.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Amends the FD&C Act to regulate drugs via safety and approval processes, potentially preempting some state laws while allowing others; could face challenges under the Administrative Procedure Act if FDA implementation is deemed arbitrary, or under product liability laws for manufacturers.
- Constitutional Implications: Relies on Congress's authority over interstate commerce and drug regulation (Commerce Clause); post-2022 Supreme Court decision in Dobbs v. Jackson Women's Health Organization (which ended federal abortion rights), this federalizes restrictions on medication abortion without directly addressing privacy or due process rights, possibly inviting lawsuits on equal protection or access to healthcare.
- Political Implications: Introduced by Republican lawmakers, it reflects a pro-life policy focus amid ongoing national debates on abortion post-Dobbs, potentially polarizing Congress and influencing midterm or future elections; no funding for maternal support is included, which could draw criticism for incompleteness.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Latta, Robert E. [R-OH-5]
Cosponsors (57)
Rep. Rouzer, David [R-NC-7], Rep. Brecheen, Josh [R-OK-2], Rep. Strong, Dale W. [R-AL-5], Rep. Miller, Mary E. [R-IL-15], Rep. Webster, Daniel [R-FL-11], Rep. Finstad, Brad [R-MN-1], Rep. Aderholt, Robert B. [R-AL-4], Rep. Feenstra, Randy [R-IA-4], Rep. Smith, Christopher H. [R-NJ-4], Rep. Fulcher, Russ [R-ID-1], Rep. Flood, Mike [R-NE-1], Rep. Mann, Tracey [R-KS-1], Rep. Harris, Andy [R-MD-1], Rep. Fong, Vince [R-CA-20], Rep. Ellzey, Jake [R-TX-6], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. McCormick, Richard [R-GA-7], Rep. Moolenaar, John R. [R-MI-2], Rep. Ogles, Andrew [R-TN-5], Rep. Guest, Michael [R-MS-3], Rep. Higgins, Clay [R-LA-3], Rep. Palmer, Gary J. [R-AL-6], Rep. Moore, Tim [R-NC-14], Rep. Shreve, Jefferson [R-IN-6], Rep. LaHood, Darin [R-IL-16], Rep. Fitzgerald, Scott [R-WI-5], Rep. Biggs, Sheri [R-SC-3], Rep. Moore, Barry [R-AL-1], Rep. Bost, Mike [R-IL-12], Rep. Fedorchak, Julie [R-ND-At Large], Rep. Thompson, Glenn [R-PA-15], Rep. Cloud, Michael [R-TX-27], Rep. Hageman, Harriet M. [R-WY-At Large], Rep. Stutzman, Marlin A. [R-IN-3], Rep. Rogers, Mike D. [R-AL-3], Rep. Kelly, Mike [R-PA-16], Rep. Hern, Kevin [R-OK-1], Rep. Kennedy, Mike [R-UT-3], Rep. Harrigan, Pat [R-NC-10], Rep. Timmons, William R. [R-SC-4], Rep. Houchin, Erin [R-IN-9], Rep. Norman, Ralph [R-SC-5], Rep. Smith, Adrian [R-NE-3], Rep. Cline, Ben [R-VA-6], Rep. Bean, Aaron [R-FL-4], Rep. Clyde, Andrew S. [R-GA-9], Rep. Steube, W. Gregory [R-FL-17], Rep. Messmer, Mark B. [R-IN-8], Rep. Cammack, Kat [R-FL-3], Rep. Onder, Robert F. [R-MO-3] and 7 more
Recent Actions
- 2025-01-23: Referred to the House Committee on Energy and Commerce.
- 2025-01-23: Introduced in House
- 2025-01-23: Introduced in House
Bill Versions
- Support And Value Expectant Moms and Babies Act of 2025 — issued 2025-01-23 — PDF (8 pages)